CD274 and neoplasm: Although some biomarkers such as PD‐L1 levels in tumor tissue, tumor mutation burden, and CD8+ tumor‐infiltrating lymphocytes, have been reported to be predictive of the efficacy of ICIs, these markers have yet to be established due to no conclusive results across tumors.30, 31, 32